Regenerative Medicine Advisory Board


Kenneth Bertram, MD, PhD, FACP

Bertram is retiring as the Principal Assistant for Acquisition for the U.S. Army Medical Research and Materiel Command (USAMRMC), Fort Detrick, Maryland, and as a member of the Senior Executive Service.  He is responsible for the advanced development and acquisition of medical products (drugs, vaccines, and devices) for the U.S. Army.  In addition, Bertram serves as the Surgeon General’s Sponsor’s Representative to the U.S. Food and Drug Administration and as the U.S. Army’s Milestone Decision Authority (MDA) for medical products and therefore is responsible for the life-cycle management of fielded medical products (research, development, acquisition, and sustainment).

More about Kenneth Bertram, MD, PhD, FACP

gregory_bonfiglio_finalGregory Bonfiglio, JD

Bonfiglio is the Founder and Managing Partner of Proteus LLC, an investment and advisory firm focused solely on regenerative medicine.  Formed in 2006, Proteus provides fund management and consulting services to the regenerative medicine industry.   Proteus works with regenerative medicine companies across all levels of development, from early stage entities to large pharma and biotech companies, as well as governmental organizations pursuing regenerative medicine initiatives. 

He is the Chairman of the Board of the Centre for Commercialization of Regenerative Medicine in Toronto, Canada.       

More about Gregory Bonfiglio, JD

Chris Mason, PhD

Dr. Mason is a Cofounder and Chief Science Officer at AvroBio, a clinical-stage, gene therapy company based in Cambridge, Massachusetts.

He also is a professor of cell and gene therapy in the Advanced Centre for Biochemical Engineering, University College London, working on the clinical translation and commercialization of cell and gene therapies. He has a multidisciplinary track record, spanning R&D, clinical practice, bioprocessing, regulation, healthcare economics, reimbursement and business.

More about Chris Mason, PhD

Philip Vanek, PhD

Vanek is General Manager of GE Healthcare’s Cell and Gene Therapy business strategy, a business initiative funded in part through GE Ventures and GE Healthymagination, a $6 billion strategy to revolutionize the world’s health by improving the quality, access and affordability of care.  Prior to joining GE, he was Head of Business Development for Cell Therapy, and later Head of Innovation, for Lonza’s pharmaceutical division, helping to drive new technology initiatives focused on cell, protein and viral therapeutic manufacturing.

Vanek’s career has included a number of innovation, business and market development roles at Becton Dickinson, Invitrogen and Life Technologies, as well as two start-up biotechnology companies in the Washington, D.C., area.

More about Philip Vanek, PhD

yaszemski_michael_finalMichael J. Yaszemski, MD, PHD

Dr. Yaszemski is the Krehbiel Family Endowed Professor of Orthopedic Surgery and Biomedical Engineering at the Mayo Clinic and director of its Biomaterials and Tissue Engineering Laboratory.

He is a retired U.S. Air Force brigadier general and served in the office of the Air Force Surgeon General and the office of the President of the Uniformed Services University of the Health Sciences prior to retiring in 2013. He served as president of the Mayo Clinic medical staff from 2013-2014, and had served for 10 years as the Chair of the Spine Surgery Division of the Department of Orthopedic Surgery at Mayo Clinic Rochester prior to entering the presidential line.

More about Michael J. Yaszemski, MD, PHD